Kim Kwang Hoe, Lee Sang Yoon, Baek Je-Hyun, Lee Soo-Youn, Kim Jin Young, Yoo Jong Shin
Research Center for Bioconvergence Analysis, Korea Basic Science Institute, Cheongju, Republic of Korea.
Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea.
Proteomics Clin Appl. 2021 Jul;15(4):e2000096. doi: 10.1002/prca.202000096. Epub 2021 Apr 9.
Fucosylation of alpha-fetoprotein (AFP) is closely correlated with the diagnosis of patients with hepatocellular carcinoma (HCC). In current, a micro-total analysis system (μTAS) using immunoassay has been developed for determining fucosylated AFP EXPERIMENTAL DESIGN: We compared two analytical methods, μTAS and liquid chromatography-parallel reaction monitoring mass spectrometry (LC-PRM MS), for the measurement of fucosylated AFP in serum to evaluate the usefulness of the results. For this purpose, serum samples were used (cirrhosis, n = 105; HCC, n = 105), and we have discussed the analytical performance of these two methods RESULTS: We observed a correlation (R = 0.84) between LC-PRM MS and μTAS using samples where fucosylated levels were measured by both methods. The fucosylated level of AFP by LC-PRM MS better differentiated between cirrhosis and HCC patients than those by μTAS (AUC = 0.910 vs. 0.861), particularly in subgroups with a level of total AFP < 20 ng/mL (0.973 vs. 0.874) and in early stage (I and II) patients (0.922 vs. 0.835) CONCLUSIONS AND CLINICAL RELEVANCE: From this comparative study we can suggest that the LC-PRM MS is applicable in the measurement of fucosylated AFP from human serum and is more useful for early diagnosis of HCC.
Fucosylation of AFP is used for the detection of HCC. A micro-total analysis system (μTAS) has been only developed for measuring fucosylation of AFP in clinical research. This study reports the fucosylation of AFP in human serum samples from cirrhosis and HCC patients using the μTAS and a LC-PRM MS to evaluate fucosylation of AFP from each method. As a result, LC-PRM MS is complementary to the conventional μTAS method. Furthermore, LC-PRM MS provides a higher diagnostic accuracy than the μTAS in patients with low AFP levels and an early stage.
甲胎蛋白（AFP）的岩藻糖基化与肝细胞癌（HCC）患者的诊断密切相关。目前，已开发出一种使用免疫测定的微全分析系统（μTAS）来测定岩藻糖基化的AFP。实验设计：我们比较了两种分析方法，即μTAS和液相色谱 - 平行反应监测质谱法（LC-PRM MS），用于测量血清中岩藻糖基化的AFP，以评估结果的实用性。为此，使用了血清样本（肝硬化，n = 105；HCC，n = 105），并且我们讨论了这两种方法的分析性能。结果：在两种方法都测量了岩藻糖基化水平的样本中，我们观察到LC-PRM MS和μTAS之间存在相关性（R = 0.84）。与μTAS相比，LC-PRM MS测定的AFP岩藻糖基化水平在区分肝硬化和HCC患者方面表现更好（AUC = 0.910对0.861），特别是在总AFP水平<20 ng/mL的亚组中（0.973对0.874）以及早期（I和II期）患者中（0.922对0.835）。结论及临床意义：通过这项比较研究，我们可以认为LC-PRM MS适用于测量人血清中岩藻糖基化的AFP，并且对HCC的早期诊断更有用。
AFP的岩藻糖基化用于HCC的检测。在临床研究中仅开发了一种微全分析系统（μTAS）来测量AFP的岩藻糖基化。本研究报告了使用μTAS和LC-PRM MS对肝硬化和HCC患者的人血清样本中AFP的岩藻糖基化情况，以评估每种方法中AFP的岩藻糖基化情况。结果表明，LC-PRM MS是对传统μTAS方法的补充。此外，在AFP水平低和早期的患者中，LC-PRM MS比μTAS具有更高的诊断准确性。
